Aug 1, 2007 by Brian LawlerElan Gets a Vote of ConfidenceElan receives a recommendation to expand the use of Tysabri.
Jul 31, 2007 by Brian LawlerAvandia Can StayThe FDA votes to allow GSK's top diabetes compound to remain on the market.
Jul 30, 2007 by Brian LawlerAmgen AdjustingAmgen's second quarter reflects the pain it's feeling with its top drugs.
Jul 30, 2007 by Brian LawlerAstraZeneca's Yawner of a QuarterThe pharma company's Q2 results are ho-hum.
Jul 30, 2007 by Brian LawlerBristol-Myers Isn't Standing in PlaceThe final quarter of stagnating financials for Bristol-Myers.
Jul 30, 2007 by Brian LawlerAtheroGenics Follows a New RouteAtheroGenics gives more details on the path forward for its lead drug.
Jul 30, 2007 by Brian LawlerIs Glaxo's Avandia Down for the Count?An FDA advisory committee is set to debate one of Glaxo's top compounds.
Jul 27, 2007 by Brian LawlerMillennium Waits for the FutureMillennium releases its second-quarter financial results.
Jul 26, 2007 by Brian LawlerGlaxo Getting Through Avandia LossGlaxo's earnings aren't hurt by the decline in Avandia sales.
Jul 26, 2007 by Brian LawlerExelixis Goes It AlonePartner Glaxo passes on codeveloping a new cancer drug.
Jul 26, 2007 by Brian LawlerFlamel Gets Stomped by GSKShares of Flamel fall as its partner doesn't focus on marketing its lead drug.
Jul 25, 2007 by Brian LawlerGPC Must WaitAn advisory panel recommends against approving GPC's lead drug right now.
Jul 25, 2007 by Brian LawlerVertex Is on Its WayVertex highlights what's ahead for the rest of the year.
Jul 24, 2007 by Brian LawlerDiscounting InterMuneShares of InterMune fall after analyst worries about one of its drugs.
Jul 24, 2007 by Brian LawlerMGI FliesShares of MGI Pharma rise after positive second-quarter results.
Jul 24, 2007 by Brian LawlerPain and Alpharma Gain From Purdue's SlipSome drugmakers gain from the government's admonishment of Purdue.
